Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05827081
Registration number
NCT05827081
Ethics application status
Date submitted
12/04/2023
Date registered
24/04/2023
Date last updated
24/04/2024
Titles & IDs
Public title
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Query!
Scientific title
A Phase IIIb Study to Characterize the Effectiveness and Safety of Adjuvant Ribociclib in a Wide Patient Population With HR+ HER2- Early Breast Cancer (Adjuvant WIDER)
Query!
Secondary ID [1]
0
0
CLEE011O12001
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Adjuvant WIDER
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Early Breast Cancer
0
0
Query!
Condition category
Condition code
Cancer
0
0
0
0
Query!
Breast
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Ribociclib
Treatment: Drugs - Letrozole
Treatment: Drugs - Ansastrozole
Treatment: Drugs - Goserelin
Treatment: Drugs - Leuprolide
Treatment: Drugs - Exemestane
Experimental: Ribociclib + endocrine therapy - Participants will receive ribociclib 400 mg orally once daily on days 1 to 21 of a 28-day cycle, in combination with daily endocrine therapy (ET) for 36 months (approximately 39 cycles). ET consists of:
For postmenopausal women: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously.
For pre/perimenopausal women, and men: letrozole 2.5 mg orally once daily continuously, anastrozole 1 mg orally once daily continuously, or exemestane 25 mg once daily continuously, combined with goserelin subcutaneously (at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used) or leuprolide subcutaneously (at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used)
Treatment: Drugs: Ribociclib
Ribociclib 400 mg orally once daily on days 1-21 of a 28 day cycle followed by 7 days rest
Treatment: Drugs: Letrozole
Letrozole 2.5 mg orally once daily continuously
Treatment: Drugs: Ansastrozole
Anastrozole 1 mg orally once daily continuously.
Treatment: Drugs: Goserelin
Goserelin administered subcutaneously at 3.6 mg once every 4 weeks if the one-month depot formulation is used or at 10.8 mg once every 3 months if the three-month depot formulation is used
Treatment: Drugs: Leuprolide
Leuprolide administered subcutaneously at 3.75 mg once every 4 weeks if the one-month depot formulation is used or at 11.25 mg once every 3 months if the three-month depot formulation is used
Treatment: Drugs: Exemestane
Exemestane 25 mg once daily continuously
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Invasive Breast Cancer Free Survival (iBCFS) rate at 3 years
Query!
Assessment method [1]
0
0
iBCFS is defined as the time from the date of first dose to the date of the first event of invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death (any cause), or contralateral invasive BC. iBCFS will be assessed using STEEP criteria version 2.0 (Standardized Definitions for Efficacy End Points in Adjuvant Breast Cancer Trials), as assessed by Investigator.
The iBCFS rate at 3 years will be assessed.
Query!
Timepoint [1]
0
0
At 3 years
Query!
Secondary outcome [1]
0
0
Invasive Disease-Free Survival (iDFS)
Query!
Assessment method [1]
0
0
iDFS is defined as the time from the date of first dose of study treatment to the date of the first event of invasive ipsilateral breast tumor recurrence, local/regional invasive recurrence, distant recurrence, death (any cause), contralateral invasive BC, or second primary non-breast invasive cancer (excluding basal and squamous cell carcinomas of the skin). iDFS will be assessed using STEEP 2.0 as assessed by the investigator.
Query!
Timepoint [1]
0
0
Up to approximately 6 years
Query!
Secondary outcome [2]
0
0
Distant Relapse-Free Survival (DRFS)
Query!
Assessment method [2]
0
0
Distant Relapse Free Survival (DRFS) is defined as the time from the date of first dose of study treatment to the date of the first event of recurrence at a distant site or death (any cause). DRFS will be assessed using STEEP 2.0 as assessed by the investigator.
Query!
Timepoint [2]
0
0
Up to approximately 6 years
Query!
Secondary outcome [3]
0
0
Recurrence-Free Interval (RFI)
Query!
Assessment method [3]
0
0
RFI is defined as the time from date of first dose to date of first event of invasive recurrence in the ipsilateral breast or locoregionally, at a distant site, or death from breast cancer. RFI will be assessed using STEEP 2.0 as per investigator assessment.
Query!
Timepoint [3]
0
0
Up to approximately 6 years
Query!
Secondary outcome [4]
0
0
Relative dose intensity (RDI) of ribociclib
Query!
Assessment method [4]
0
0
RDI is defined as the ratio of the dose intensity delivered to the planned dose intensity.
Query!
Timepoint [4]
0
0
Up to 3 years
Query!
Secondary outcome [5]
0
0
Overall Survival (OS)
Query!
Assessment method [5]
0
0
OS is defined as time from the start of study treatment to date of death due to any cause.
Query!
Timepoint [5]
0
0
Up to approximately 6 years
Query!
Secondary outcome [6]
0
0
Time To Discontinuation (TTD) of ribociclib
Query!
Assessment method [6]
0
0
TTD is defined as the time from starting ribociclib to the time to treatment discontinuation due to any cause.
Query!
Timepoint [6]
0
0
Up to 3 years
Query!
Secondary outcome [7]
0
0
Changes from baseline in Functional Assessment of Cancer Therapy - Breast (FACT-B) score
Query!
Assessment method [7]
0
0
The FACT-B is a questionnaire that consists of 37 items with items from FACT-General (FACT-G) questionnaire (27 items) and from the Breast Cancer Subscale (BCS, 10 items). FACT-B consists of five subscales that address different aspects of the participant's quality of life: physical well-being (PWB), social/family well-being (SWB), emotional well-being (EWB), functional well-being (FWB), and BCS.
Query!
Timepoint [7]
0
0
Up to approximately 6 years
Query!
Secondary outcome [8]
0
0
Changes from baseline in Functional Assessment of Cancer Therapy - Endocrine Symptoms (FACT-ES) score
Query!
Assessment method [8]
0
0
The FACT-ES is a questionnaire that consists of 19 items which assesses endocrine complaints and adverse events.
Query!
Timepoint [8]
0
0
Up to approximately 6 years
Query!
Secondary outcome [9]
0
0
Changes from baseline in Functional Assessment of Chronic Illness Therapy - Fatigue (FACIT-F) score
Query!
Assessment method [9]
0
0
The FACIT-F is a 13-item questionnaire designed to assess self-reported fatigue and its impact on daily activities and functions.
Query!
Timepoint [9]
0
0
Up to approximately 6 years
Query!
Secondary outcome [10]
0
0
Changes from baseline in European Quality of Life-5 Dimensions (EQ-5D-5L) score
Query!
Assessment method [10]
0
0
EQ-5D-5L is a standardized participant completed questionnaire that measures health-related quality of life and translates that score into an index value or utility score. EQ-5D-5L consists of two components: a health state profile and an optional visual analogue scale (VAS). EQ-5D-5L health state profile is comprised of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression.
Query!
Timepoint [10]
0
0
Up to approximately 6 years
Query!
Secondary outcome [11]
0
0
Changes from baseline in Work Productivity and Activity Impairment Questionnaire (WPAI-GH) score
Query!
Assessment method [11]
0
0
WPAI-GH measures the impact of health problems on the participant's productivity, in paid or unpaid activities, in the last 7 days. It is 6-item scale measuring absenteeism, presenteeism, and impairments in unpaid activity.
Query!
Timepoint [11]
0
0
Up to approximately 6 years
Query!
Eligibility
Key inclusion criteria
Key
- Participant has a histologically and/or cytologically confirmed diagnosis of
estrogen-receptor positive and/or progesterone receptor positive breast cancer
- Participant has HER2-negative breast cancer
- Participants may have already received any standard neoadjuvant and/or adjuvant ET,
including tamoxifen or toremifene, at the time of informed consent signature, but
enrollment should occur within 36 months of prior ET start date and the participant
should have at least 3 years remaining of endocrine adjuvant therapy. For participants
with prior ET treatment > 12 months, the investigator should rule out disease
recurrence prior to enrollment. The number of participants with prior ET between 12
and 36 months will be capped at 1000.
- Participant has no contraindication for the adjuvant ET in the study.
- Participant after complete surgical resection with the final surgical specimen
microscopic margins free from tumor and in one of below categories:
- Anatomic Stage Group III
- Anatomic Stage Group II (subset)
- Anatomic Stage Group I (high-risk subset as exploratory cohort)
- Participant has an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0,1
or 2.
- Participant has adequate bone marrow and organ function.
Key
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
- Participant with distant metastases of breast cancer beyond regional lymph nodes
(stage IV according to AJCC 8th edition) and/or evidence of recurrence after curative
surgery.
- Participant is concurrently using other anti-neoplastic therapy with the exception of
adjuvant ET.
- Participant has any other concurrent severe and/or uncontrolled medical condition
- Clinically significant, uncontrolled heart disease and/or cardiac repolarization
abnormality.
- Pregnant or breast-feeding (lactating) women or women who plan to become pregnant or
breast-feed during the trial.
Other inlcusion/exclusion criteria may apply
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
N/A
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Single group
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Suspended
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
28/02/2024
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
20/09/2030
Query!
Actual
Query!
Sample size
Target
3100
Query!
Accrual to date
Query!
Final
Query!
Recruitment in Australia
Recruitment state(s)
NSW
Query!
Recruitment hospital [1]
0
0
Novartis Investigative Site - Gateshead
Query!
Recruitment postcode(s) [1]
0
0
2290 - Gateshead
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
Novartis Pharmaceuticals
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
An open-label, multicenter, phase IIIb, single-arm study to evaluate the safety and efficacy
of the combination of ribociclib and standard adjuvant endocrine therapy (ET) on invasive
breast cancer-free survival (iBCFS), in a wide patient population with HR-positive (HR+),
HER2-negative (HER2-), Anatomic Stage Group III, II (subset) or I (high-risk subset as
exploratory cohort) early Breast Cancer (EBC)
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05827081
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Novartis Pharmaceuticals
Query!
Address
0
0
Novartis Pharmaceuticals
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05827081
Download to PDF